N. Shaabani

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

This study systematically evaluates dipeptidyl inhibitors of SARS-CoV-2 main protease, identifying compounds with high antiviral potency and low cytotoxicity.

Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection

This paper develops aminoadamantane nitrate compounds that inhibit SARS-CoV-2 infection by S-nitrosylating ACE2 and blocking viral entry, showing efficacy in vitro and in a Syrian hamster model.

Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta

This study develops a chimeric mRNA vaccine that provides broad protection against Omicron and Delta variants of SARS-CoV-2 by combining RBDs from different variants.

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape

This study engineers SARS-CoV-2 neutralizing antibodies through directed evolution to enhance their potency and reduce viral escape.

The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors

This paper identifies that a P4 N-terminal carbamate in boceprevir-based inhibitors is crucial for high antiviral potency against SARS-CoV-2.

The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors

This study identifies O-tert-butyl-threonine at the P3 site as critical for enhancing cellular and antiviral potency of MPro inhibitors.

Directing an mRNA-LNP vaccine toward lymph nodes improves humoral and cellular immunity against SARS-CoV-2

This study develops an mRNA-LNP vaccine (STI-7264) and a lymphatic delivery device (MuVaxx) that enhance immune responses against SARS-CoV-2 with reduced dosing.

Protein-based RBD-C-tag COVID-19 Vaccination Candidate Elicits Protection Activity against SARS-COV-2 Variant Infection

This study shows that a protein-based RBD-C-tag vaccine candidate provides protection against multiple SARS-COV-2 variants in mice.

Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics

This paper evaluates the cellular potency of SARS-CoV-2 MPro inhibitors using a fluorescent flow cytometry assay, revealing that most inhibitors have weak cellular activity despite strong antiviral effects.

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

TLR9-activated B cells improve their regulatory function by endogenously produced catecholamines

This study shows that TLR9-activated B cells produce catecholamines, enhancing their regulatory function through adrenergic receptor activation and increased IL-10 and co-inhibitory ligand expression.

ISG15 drives immune pathology and respiratory failure during viral infection

This study shows that lack of deISGylation during viral infection leads to immune pathology and respiratory failure, with extracellular ISG15 playing a key role in inflammation and disease severity.